Afleveringen
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the rapidly evolving world of CAR T cell therapy, a groundbreaking treatment for various hematologic malignancies. Joined by experts Dr. Surbhi Sidana from Stanford University and Dr. Jason Westin from MD Anderson Cancer Center, we explore the mechanism of action of CAR T cells, their side effects, and management strategies.
Episode Highlights:
Understanding CAR T cell therapy and its application in hematologic malignancies and solid tumors.Mechanism of action: How CAR T cells are engineered to target cancer cells.Acute side effects: Cytokine release syndrome (CRS) and neurotoxicity, including clinical pearls for management.Chronic side effects: Monitoring for infections, cytopenias, and the risk of secondary malignancies.The importance of bridging therapy and managing tumor burden before CAR T treatment.Insights for community oncologists on patient management and communication with CAR T centers.Join us for an informative discussion that emphasizes the importance of recognizing and managing the unique side effects of CAR T therapy to ensure the best outcomes for patients. Don't forget to check out our other episodes for more insights into recent advances in hematology and oncology!
Subscribe for more discussions on FDA approvals, treatment algorithms, and conference highlights. We are the Oncology Brothers!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome back to the Oncology Brothers podcast! In this episode, we dive into the highlights from ASH 2024, focusing on key studies in leukemia. Join hosts Drs. Rahul and Rohit Gosain as they discuss groundbreaking research with Dr. Uma Borate from The Ohio State University.
Episode Highlights:• KOMET 007 Study: An in-depth look at the Phase 1 study on the Menin inhibitor Ziftomenib, exploring its promising results in frontline settings for patients with NPM1 mutations and KMT2A rearrangements.• CPX351 vs. 7+3 Induction: A discussion on the liposomal formulation CPX351 and its effectiveness compared to the traditional 7+3 induction therapy, particularly in patients with myelodysplasia-related AML.• Venetoclax Combinations: Insights into the use of Venetoclax in combination with various therapies, including its role in treating patients without actionable mutations.
Key Takeaways:• The importance of NGS testing in identifying targetable mutations in AML.• Promising response rates and manageable toxicities associated with Menin inhibitors.• The ongoing debate regarding the best induction therapy for AML patients.
Don't miss this informative discussion that sheds light on the evolving landscape of leukemia treatment!
Subscribe for more updates on oncology topics, including lymphoma, CLL, and myeloma discussions from ASH 2024. Thanks for tuning in! We are the Oncology Brothers.
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Zijn er afleveringen die ontbreken?
-
In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch.
The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as:
How to approach sequencing in clinical practiceThe available data supporting sequencing strategiesWhen to switch to 2nd line therapy and what to consider when doing soThis is the second video podcast episode in a 4-part series. Access the rest of the series here:
Part 1 - The use of IO in unresectable HCC
Part 3 - Intermediate HCC: treatment options and strategies (coming soon)
Part 4 - The evolving role of IO in intermediate HCC (coming soon)
Clinical takeaways
Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisionsWhen switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life.Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be consideredManaging side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease managementEffective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to another episode of the Oncology Brothers! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Joined by expert guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from Sarah Cannon Research Institute, the discussion focuses on three key ADCs: Enfortumab vedotin, Sacituzumab govitecan, and Trastuzumab deruxtecan (TDXD).
Episode Highlights:• Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice.• Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care.• Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management.
This episode emphasizes the importance of recognizing and acting on side effects that can significantly impact patient outcomes. Whether you're a healthcare professional or someone interested in oncology, this discussion will provide valuable insights into toxicity management for ADCs.
Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data. Topics also include: • Efficacy and safety of IO and IO combinations in HCC• How to select between the two 1st-line IO-based treatment options based on clinical factors• Future treatment in unresectable HCC Clinical Takeaways• Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary• In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study.
Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations.
Key topics discussed include:• Overview of the INAVO120 study and its significance• The unique patient population targeted in the study• Key findings, including the impressive improvement in progression-free survival (PFS)• Side effects and management strategies for patients• The importance of genetic testing in treatment decisions
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment.
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!#OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rohit and Rahul Gosain are joined by Dr. Eileen O'Reilly, a leading medical oncologist and section head of hepatobiliary and pancreatic cancer at Memorial Sloan Kettering Cancer Center. Together, they delve into the complex treatment landscape of pancreatic cancer.
Episode Highlights:
The initial workup for newly diagnosed pancreatic cancer patients, including the importance of imaging and genetic testing. Treatment paradigms for early-stage, borderline resectable, and metastatic pancreatic cancer. The role of multi-agent chemotherapy, including modified FOLFIRINOX and gemcitabine-nab-paclitaxel. Insights into managing patients with high bilirubin levels and the considerations for dose adjustments. The emerging role of targeted therapies and the significance of comprehensive genetic testing in treatment decisions.Join us as we explore the latest standards of care, the importance of a multidisciplinary approach, and the potential of new therapies in improving outcomes for patients with pancreatic cancer.
Don't forget to like, subscribe, and check out our other episodes for more insights on oncology topics, conference highlights, and recent treatment approvals!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Neil Iyengar, a medical oncologist from Memorial Sloan Kettering Cancer Center, to discuss the critical role of nutrition and exercise in cancer care and recurrence prevention.They tackle common questions from cancer survivors about lifestyle modifications that can help reduce the risk of cancer recurrence. With the current hype around various diets, the discussion delves into the evidence surrounding dietary patterns, exercise, and their impact on overall health and cancer outcomes.
Key topics included:• The mixed evidence regarding diet and exercise in preventing cancer recurrence.• The limitations of BMI as a measure of health and its implications in cancer studies.• Insights from recent breast cancer trials on diet and survival rates.• The importance of social determinants of health in dietary recommendations.• Practical dietary guidelines and the significance of high-fiber, fruit-and-vegetable-rich diets.
Dr. Iyengar emphasized the need for ongoing research to provide more specific dietary recommendations for different cancer types and highlights resources available for patients and healthcare providers.
Join us for an informative discussion that aimed to empower cancer patients and healthcare professionals with knowledge about lifestyle interventions that can enhance quality of life and potentially improve cancer outcomes.
Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rohit and Rahul Gosain welcome Dr. Pamela Kunz, a world-renowned medical oncologist from the Yale Cancer Center, to discuss the complex landscape of neuroendocrine tumors (NETs).
Join us as we explore:• The classification of neuroendocrine tumors based on grade, histological features, and the significance of KI-67.• The role of imaging modalities, including Gallium PET-CT and its importance in evaluating disease extent.• Treatment strategies for localized versus metastatic NETs, including the use of somatostatin analogs and the nuances of observation versus intervention.• Insights into the latest treatment options, including lutetium dotatate, Capecitabine-Temozolomide, and the anticipated approval of Cabozantinib.• The potential role of NGS testing and the challenges of combining chemotherapy with immunotherapy in high-grade neuroendocrine tumors.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the management of neuroendocrine tumors.
Don't forget to like, subscribe, and check out our other episodes for more discussions on current standard of care treatment options, conference highlights, and new drug approvals. We look forward to seeing you at GI ASCO in January 2025!
#OncologyBrothers #NeuroendocrineTumors #CancerCare #MedicalOncology #Podcast #NETs
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by esteemed palliative care experts Dr. Janet Abrahm from Dana-Farber Cancer Institute and Dr. Ishwaria Subbiah from Sarah Cannon Research Institute. Together, they delve into the critical topic of palliative care, exploring its evolution from a focus on end-of-life care to an integral part of cancer treatment that enhances both longevity and quality of life.
Key discussion points include:• The definition and importance of palliative care as an "extra layer of support" for patients, families, and oncologists.• The stigma surrounding palliative care and the potential benefits of rebranding it as supportive care.• The significant impact of palliative care on symptom management and overall patient outcomes.• Innovative approaches to integrating palliative care into oncology practices, including the use of technology and multidisciplinary teams.• Effective communication strategies for discussing palliative care and advanced care planning with patients and their families.
Join us for this enlightening conversation that aims to demystify palliative care and highlight its essential role in cancer care. Don't forget to like, subscribe, and share your thoughts in the comments!#OncologyBrothers #PalliativeCare #CancerCare #SupportiveCare #QualityOfLife #SymptomManagement #AdvancedCarePlanning
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain welcome Dr. Martina Murphy, an Associate Professor of Medicine and Senior Associate Dean of Graduate Medical Education at the University of Florida, to discuss the current landscape of ovarian cancer.
Join us as we dive into the critical aspects of diagnosing and managing ovarian cancer, including:• The importance of surgical staging and primary debulking surgery• The role of genetic testing, including BRCA and NGS, in treatment planning• Adjuvant therapy options, focusing on platinum-based chemotherapy and the use of Bevacizumab• Insights into PARP inhibitors and their application in BRCA-positive and wild-type patients• Navigating treatment options for relapsed and refractory ovarian cancer, including the use of antibody-drug conjugates like Mirvetuximab and Trastuzumab Deruxtecan (TDXd).
Dr. Murphy shares her expertise on the latest advancements in ovarian cancer treatment, the significance of genetic testing, and the management of side effects associated with various therapies.
Tune in for a comprehensive overview of the standard of care for ovarian cancer and the evolving treatment landscape. Don't forget to check out our other episodes for more discussions on practice-changing data and current treatment options in oncology!
Subscribe to the Oncology Brothers podcast for more insights and updates in the field of oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of gynecologic oncology, focusing specifically on endometrial cancer. Hosted by Drs. Rohit and Rahul Gosain, this episode features Dr. Shannon Westin, a Professor of Gynecology, Oncology, and Reproductive Medicine at the MD Anderson Cancer Center.
In this episode, we explored:• The different histologies of endometrial cancer, including endometrioid, serous, clear cell, and undifferentiated types.• The evolving landscape of molecular classification and its impact on treatment decisions.• The current treatment paradigms for early-stage and advanced endometrial cancer, including the role of surgery, chemotherapy, and immunotherapy.• The significance of NGS (Next-Generation Sequencing) testing in identifying actionable mutations, such as MSI-high tumors and HER2-positive cancers.• The latest advancements in adjuvant therapies and the potential of combining chemotherapy with immunotherapy.
Whether you're a healthcare professional or simply interested in the latest developments in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't forget to like, subscribe, and check out our other discussions focusing on ovarian cancer and more!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.
Key topics discussed include:• The study's primary endpoint of objective response rate and its implications for patient care.• The unique mechanism of action of tarlatamab targeting DLL3 and CD3 T cells.• The importance of monitoring for side effects such as cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).• Strategies for community oncologists to effectively manage patients receiving this new treatment.
Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.
Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent approval of Durvalumab in the perioperative settings for non-small cell lung cancer, based on the AEGEAN trial.
Join us as we welcome Dr. Sandip Patel, a medical oncologist from UCSD, and Dr. Mara Antonoff, a thoracic surgeon from MD Anderson, to discuss the implications of this new treatment option. We explore the study design of the AEGEAN trial, its differences from other trials like Keynote 671, and the importance of a multidisciplinary approach in managing lung cancer patients.
Key topics include: • Overview of the AGEAN trial and its findings • The significance of neoadjuvant and adjuvant therapies • The role of surgical evaluation and molecular profiling • Insights on patient selection and treatment strategies
As we shift towards more perioperative and postoperative treatments, understanding the nuances of these approaches is crucial for optimizing patient outcomes. Tune in for valuable insights and discussions that can help shape your practice!
Don't forget to like, subscribe, and hit the notification bell for more episodes on recent approvals and practice-changing data in oncology! #OncologyBrothers #LungCancer #Dervalumab #AEGEANTrial #MultidisciplinaryCare #MedicalOncology #ThoracicSurgery
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together, they dive into the latest findings from ESMO 2024, focusing on key studies in lung cancer that every community oncologist should be aware of.
Episode Highlights:• LAURA Trial: Discussing the role of osimertinib in locally advanced unresectable EGFR-mutant lung cancer post-chemoradiation and its impact on CNS progression-free survival.• MARIPOSA and MARIPOSA-2 Studies: Exploring the importance of amivantamab in metastatic non-small cell lung cancer, including insights on resistance patterns and treatment sequencing.• ADRIATIC Study: Analyzing the use of durvalumab as consolidation therapy in limited-stage small cell lung cancer and its implications for practice, including updates on prophylactic cranial irradiation (PCI).
Join us as we unpack these pivotal studies that are shaping the future of lung cancer treatment. Don't forget to check out our highlights on GI, GU, and breast cancer from ESMO 2024!
Subscribe for more insights and updates in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers Podcast, hosts Drs. Rohit and Rahul Gosain welcome Dr. Shernan Holtan from Roswell Park Comprehensive Cancer Center to discuss the recent approval of Axatilimab, a novel monoclonal antibody for the treatment of chronic graft-versus-host disease (GVHD).
Join us as we explore the differences between acute and chronic GVHD, the challenges faced by community oncologists in managing this condition, and the exciting results from the AGAVE-201 study that led to Axatilimab's FDA approval. Dr. Holtan shares insights on the drug's mechanism of action, its dosing regimen, and the importance of patient-reported outcomes in assessing treatment efficacy.
We also delve into the safety profile of Axatilimab, discussing potential side effects, infusion reactions, and the significance of partnering with tertiary care centers for optimal patient management.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on managing chronic GVHD and improving patient quality of life.
Don't forget to like, subscribe, and check out our other episodes for more discussions on recent approvals and the current standard of care for various malignancies!#OncologyBrothers #GVHD #Axatilimab #ChronicGVHD #CancerCare #Podcast
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Mikkael Sekeres, Professor of Medicine and Chief of the Division of Hematology at the University of Miami. Together, they explore the complex landscape of acute myeloid leukemia (AML), discussing the latest advancements in diagnosis, treatment options, and risk stratification.
Key topics included:
• The importance of molecular testing in AML diagnosis and treatment planning
• The role of intensive induction chemotherapy and the classic 7+3 regimen
• New oral therapies, including FLT3 inhibitors and hypomethylating agents combined with venetoclax
• Strategies for managing elderly or frail patients who are ineligible for intensive chemotherapy
• The significance of measurable residual disease (MRD) in treatment decisions and transplant eligibility
• Insights into managing side effects and complications associated with AML treatments
Join us for an informative discussion that sheds light on the evolving treatment landscape of AML and the importance of personalized care in oncology. Don't forget to check out our other episodes on hematological malignancies, and we look forward to seeing you at ASH 2024!
Subscribe to our channel for more insights and updates in the world of oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Join us in this exciting episode of the Oncology Brothers podcast as we dive into the highlights from ESMO 2024, focusing on gastrointestinal malignancies. Hosts Drs. Rohit and Rahul Gosain are joined by Dr. Kristen Ciombor, a GI medical oncologist from Vanderbilt University, to discuss four key studies that have significant implications for clinical practice.
In this episode, we covered:• LEAP-012 Study: An update on HCC treatment with Lenvatinib and Pembrolizumab combined with TACE, exploring the promising progression-free survival (PFS) data and the need for mature overall survival (OS) results.• Keynote-811: The current standard of care for HER2-positive gastroesophageal junction and gastric adenocarcinoma, highlighting improved OS with Pembrolizumab, chemotherapy, and Trastuzumab.• POD1UM-303 Trial: A groundbreaking study in metastatic anal cancer that shows significant OS improvement with the addition of the PD-1 inhibitor Retifanlimab to chemotherapy.• NICHE-2 Study: A remarkable update on MSI-high patients, showcasing a 100% three-year disease-free survival rate with neoadjuvant immunotherapy.
Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don't forget to like, subscribe, and hit the notification bell for more conference highlights and oncology discussions.#OncologyBrothers #ESMO24 #GIMalignancies #CancerResearch #Podcast
Subscribe for more updates and insights from the Oncology Brothers!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Join us as we dive into four pivotal studies:
1. NIAGARA Trial: Explore the groundbreaking findings on the combination of chemotherapy and immunotherapy in the perioperative setting for patients with resectable muscle-invasive bladder cancer, which may now set a new standard of care.
2. TiNiVO-2 Study: Learn why re-challenging patients with immunotherapy after progression on prior immunotherapy is not recommended, and what alternative treatments may be more effective.
3. PEACE-3 Study: Discover the implications of combining enzalutamide with radium-223 in metastatic castration-resistant prostate cancer and its impact on progression-free survival.
4. CONTACT-02 Study: Understand the results comparing cabozantinib with atezolizumab against a second novel hormonal therapy, and what this means for overall survival in specific patient populations.
Tune in for an insightful discussion that highlights the latest advancements in GU cancer treatment and their potential impact on clinical practice. Don't forget to check out our other episodes covering breast cancer, lung cancer, and GI malignancies from ESMO 2024!
Subscribe for more updates and insights from the Oncology Brothers!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Paolo Tarantino from the Dana-Farber Cancer Institute to discuss the latest highlights from ESMO 2024, focusing on groundbreaking studies in breast cancer.
Join us as we dive into three key abstracts that have the potential to impact current clinical practice:
1. NATALEE Trial: Discover how the addition of ribociclib to endocrine therapy has shown improved invasive disease-free survival in early-stage breast cancer, including node-negative patients. Ribociclib was recently approved for this indication, and we discuss its implications for patient care.
2. Keynote 522 Update: We explore the updated results demonstrating an overall survival benefit with the perioperative use of pembrolizumab in combination with neoadjuvant chemotherapy for early-stage triple-negative breast cancer. This regimen continues to be a standard of care.
3. DESTINY Breast-12: Learn about the promising intracranial activity of trastuzumab durextecan in HER2-positive breast cancer patients with brain metastases, showcasing its potential to change treatment trajectories.
Tune in for an insightful discussion that highlights the evolving landscape of breast cancer treatment and offers hope for patients. Don't forget to check out our other episodes covering GI, lung, and GU cancer conference highlights!
Subscribe for more updates and insights from the Oncology Brothers!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
- Laat meer zien
